Lung parenchyma-derived IL-6 promotes IL-17A-dependent acute lung injury after allogeneic stem cell transplantation

Blood

Volumn 125, Issue 15, 2015, Pages 2435-2444

  Varelias, Antiopi ^a   Gartlan, Kate H ^a   Kreijveld, Ellen ^a   Olver, Stuart D ^a   Lor, Mary ^a   Kuns, Rachel D ^a   Lineburg, Katie E ^a   Teal, Bianca E ^a   Raffelt, Neil C ^a   Cheong, Melody ^a   Alexander, Kylie A ^a   Koyama, Motoko ^a   Markey, Kate A ^a   Sturgeon, Elise ^a,b   Leach, Justine ^a,b   Reddy, Pavan ^c   Kennedy, Glen A ^a,b   Yanik, Gregory A ^c   Blazar, Bruce R ^d   Tey, Siok Keen ^a,b   Clouston, Andrew D ^e   MacDonald, Kelli P A ^a   Cooke, Kenneth R ^f   Hill, Geoffrey R ^a,b   more..

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^b ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^c UNIVERSITY OF MICHIGAN   (United States)

^d UNIVERSITY OF MINNESOTA   (United States)

^e Envoi Specialist Pathologists ^*  (Australia)

^f JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; GAMMA INTERFERON; INTERLEUKIN 17; INTERLEUKIN 6; METHOTREXATE; STEROID; TUMOR NECROSIS FACTOR INHIBITOR; IMMUNOSUPPRESSIVE AGENT;

ACUTE LUNG INJURY; ALLOGENEIC STEM CELL TRANSPLANTATION; ANIMAL CELL; ANIMAL MODEL; ARTICLE; CD4+ T LYMPHOCYTE; CELL DIFFERENTIATION; CONTROLLED STUDY; CYTOKINE RELEASE; FEMALE; GRAFT VERSUS HOST REACTION; HELPER CELL; IDIOPATHIC DISEASE; IDIOPATHIC PNEUMONIA SYNDROME; IMMUNE DYSREGULATION; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; LUNG PARENCHYMA; MOUSE; NONHUMAN; PARENCHYMA CELL; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; STEROID THERAPY; T LYMPHOCYTE; TH17 CELL; ADVERSE EFFECTS; ALLOTRANSPLANTATION; ANIMAL; BAGG ALBINO MOUSE; C57BL MOUSE; DRUG EFFECTS; IMMUNOLOGY; LUNG; PATHOLOGY; STEM CELL TRANSPLANTATION;

ACUTE LUNG INJURY; ANIMALS; CYCLOSPORINE; FEMALE; IMMUNOSUPPRESSIVE AGENTS; INTERFERON-GAMMA; INTERLEUKIN-17; INTERLEUKIN-6; LUNG; MICE, INBRED BALB C; MICE, INBRED C57BL; STEM CELL TRANSPLANTATION; TH17 CELLS; TRANSPLANTATION, HOMOLOGOUS;

EID: 84927511163     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-07-590232     Document Type: Article

References (43)

1. Ferrara JL, Levine JE, Reddy P, Holler E. Graft-versus-host disease. Lancet. 2009;373(9674):1550-1561.
2. Clark JG, Hansen JA, Hertz MI, Parkman R, Jensen L, Peavy HH. NHLBI workshop summary. Idiopathic pneumonia syndrome after bone marrow transplantation. Am Rev Respir Dis. 1993;147(6 pt 1):1601-1606.
3. Panoskaltsis-Mortari A, Griese M, Madtes DK, et al American Thoracic Society Committee on Idiopathic Pneumonia Syndrome. An official American Thoracic Society research statement: noninfectious lung injury after hematopoietic stem cell transplantation: idiopathic pneumonia syndrome. Am J Respir Crit Care Med. 2011;183(9):1262-1279.
4. Yanik G, Cooke KR. The lung as a target organ of graft-versus-host disease. Semin Hematol. 2006;43(1):42-52.
5. Burman AC, Banovic T, Kuns RD, et al. IFNgamma differentially controls the development of idiopathic pneumonia syndrome and GVHD of the gastrointestinal tract. Blood. 2007;110(3):1064-1072.
6. Mauermann N, Burian J, von Garnier C, et al. Interferon-gamma regulates idiopathic pneumonia syndrome, a Th17+CD4+ T-cell-mediated graft-versus-host disease. Am J Respir Crit Care Med. 2008;178(4):379-388.
7. Hirota K, Duarte JH, Veldhoen M, et al. Fate mapping of IL-17-producing T cells in inflammatory responses. Nat Immunol. 2011;12(3):255-263.
8. Koyama M, Kuns RD, Olver SD, et al. Recipient nonhematopoietic antigen-presenting cells are sufficient to induce lethal acute graft-versus-host disease. Nat Med. 2011;18(1):135-142.
9. Morris ES, MacDonald KP, Rowe V, et al. NKT cell-dependent leukemia eradication following stem cell mobilization with potent G-CSF analogs. J Clin Invest. 2005;115(11):3093-3103.
10. Morris ES, MacDonald KP, Rowe V, et al. Donor treatment with pegylated G-CSF augments the generation of IL-10-producing regulatory T cells and promotes transplantation tolerance. Blood. 2004;103(9):3573-3581.
11. Hill GR, Olver SD, Kuns RD, et al. Stem cell mobilization with G-CSF induces type 17 differentiation and promotes scleroderma. Blood. 2010;116(5):819-828.
12. Cooke KR, Kobzik L, Martin TR, et al. An experimental model of idiopathic pneumonia syndrome after bone marrow transplantation: I. The roles of minor H antigens and endotoxin. Blood. 1996;88(8):3230-3239.
13. Tawara I, Koyama M, Liu C, et al. Interleukin-6 modulates graft-versus-host responses after experimental allogeneic bone marrow transplantation. Clin Cancer Res. 2011;17(1):77-88.
14. Hill GR, Crawford JM, Cooke KR, Brinson YS, Pan L, Ferrara JLM. Total body irradiation and acute graft-versus-host disease: the role of gastrointestinal damage and inflammatory cytokines. Blood. 1997;90(8):3204-3213.
15. Hill GR, Ferrara JLM. The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease: rationale for the use of cytokine shields in allogeneic bone marrow transplantation. Blood. 2000;95(9):2754-2759.
16. Panoskaltsis-Mortari A, Taylor PA, Yaeger TM, et al. The critical early proinflammatory events associated with idiopathic pneumonia syndrome in irradiated murine allogeneic recipients are due to donor T cell infusion and potentiated by cyclophosphamide. J Clin Invest. 1997;100(5):1015-1027.
17. Borsotti C, Franklin AR, Lu SX, et al. Absence of donor T-cell-derived soluble TNF decreases graft-versus-host disease without impairing graft-versus-tumor activity. Blood. 2007;110(2):783-786.
18. Serody JS, Hill GR. The IL-17 differentiation pathway and its role in transplant outcome. Biol Blood Marrow Transplant. 2012;18(suppl 1):S56-S61.
19. Hirano T. Interleukin 6 and its receptor: ten years later. Int Rev Immunol. 1998;16(3-4):249-284.
20. Zhang M, Yin L, Zhang K, et al. Response patterns of cytokines/chemokines in two murine strains after irradiation. Cytokine. 2012;58(2):169-177.
21. Smith PD, Ochsenbauer-Jambor C, Smythies LE. Intestinal macrophages: unique effector cells of the innate immune system. Immunol Rev. 2005;206:149-159.
22. Constant SL, Brogdon JL, Piggott DA, et al. Resident lung antigen-presenting cells have the capacity to promote Th2 T cell differentiation in situ. J Clin Invest. 2002;110(10):1441-1448.
23. Persson EK, Uronen-Hansson H, Semmrich M, et al. IRF4 transcription-factor-dependent CD103(+)CD11b(+) dendritic cells drive mucosal T helper 17 cell differentiation. Immunity. 2013;38(5):958-969.
24. Liu J, Farmer JD Jr, Lane WS, Friedman J, Weissman I, Schreiber SL. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell. 1991;66(4):807-815.
25. Schreiber SL, Crabtree GR. The mechanism of action of cyclosporin A and FK506. Immunol Today. 1992;13(4):136-142.
26. Kiani A, Rao A, Aramburu J. Manipulating immune responses with immunosuppressive agents that target NFAT. Immunity. 2000;12(4):359-372.
27. Tsuda K, Yamanaka K, Kitagawa H, et al. Calcineurin inhibitors suppress cytokine production from memory T cells and differentiation of naive T cells into cytokine-producing mature T cells. PLoS One. 2012;7(2):e31465.
28. Lemaître PH, Vokaer B, Charbonnier LM, et al. Cyclosporine A drives a Th17- and Th2-mediated posttransplant obliterative airway disease. Am J Transplant. 2013;13(3):611-620.
29. Kennedy GA, Varelias A, Vuckovic S, et al. Addition of interleukin-6 inhibition with tocilizumab to standard graft-versus-host disease prophylaxis after allogeneic stem-cell transplantation: a phase 1/2 trial. Lancet Oncol. 2014;15(13):1451-1459.
30. Hildebrandt GC, Olkiewicz KM, Corrion LA, et al. Donor-derived TNF-alpha regulates pulmonary chemokine expression and the development of idiopathic pneumonia syndrome after allogeneic bone marrow transplantation. Blood. 2004;104(2):586-593.
31. Gerbitz A, Nickoloff BJ, Olkiewicz K, et al. A role for tumor necrosis factor-alpha-mediated endothelial apoptosis in the development of experimental idiopathic pneumonia syndrome. Transplantation. 2004;78(4):494-502.
32. Cooke KR, Hill GR, Gerbitz A, et al. Tumor necrosis factor-alpha neutralization reduces lung injury after experimental allogeneic bone marrow transplantation. Transplantation. 2000;70(2):272-279.
33. Clark JG, Mandac JB, Dixon AE, Martin PJ, Hackman RC, Madtes DK. Neutralization of tumor necrosis factor-alpha action delays but does not prevent lung injury induced by alloreactive T helper 1 cells. Transplantation. 2000;70(1):39-43.
34. Yanik GA, Ho VT, Levine JE, et al. The impact of soluble tumor necrosis factor receptor etanercept on the treatment of idiopathic pneumonia syndrome after allogeneic hematopoietic stem cell transplantation. Blood. 2008;112(8):3073-3081.
35. Tizon R, Frey N, Heitjan DF, et al. High-dose corticosteroids with or without etanercept for the treatment of idiopathic pneumonia syndrome after allo-SCT. Bone Marrow Transplant. 2012;47(10):1332-1337.
36. Yanik G, Grupp S, Pulsipher MA, et al. Competitive TNF inhibitor (ETANERCEPT) for the treatment of idiopathic pneumonia syndrome (IPS) following allogeneic stem cell transplantation (SCT). A Joint Pediatric Blood and Marrow Transplant Consortium (PBMTC) and Children's Oncology Group (COG) Study. Biol Blood Marrow Transplant. 2013;19(supp 2):S111-S112.
37. Yanik GA, Horowitz MH, Weisdorf DJ, et al. Randomized, double-blind, placebo-controlled trial of a soluble tumor necrosis factor receptor: Enbrel (Etanercept) for the treatment of idiopathic pneumonia syndrome after allogeneic stem cell transplantation: Blood and Marrow Transplant Clinical Trials Network Protocol. Biol Blood Marrow Transplant. 2014;20(6):858-864.
38. Yi T, Chen Y, Wang L, et al. Reciprocal differentiation and tissue-specific pathogenesis of Th1, Th2, and Th17 cells in graft-versus-host disease. Blood. 2009;114(14):3101-3112.
39. Cavet J, Dickinson AM, Norden J, Taylor PR, Jackson GH, Middleton PG. Interferon-gamma and interleukin-6 gene polymorphisms associate with graft-versus-host disease in HLA-matched sibling bone marrow transplantation. Blood. 2001;98(5):1594-1600.
40. Dickinson AM, Middleton PG, Rocha V, Gluckman E, Holler E; Eurobank members. Genetic polymorphisms predicting the outcome of bone marrow transplants. Br J Haematol. 2004;127(5):479-490.
41. Chien JW, Zhang XC, Fan W, et al. Evaluation of published single nucleotide polymorphisms associated with acute GVHD. Blood. 2012;119(22):5311-5319.
42. Dickinson AM. SNPs and GVHD prediction: where to next? Blood. 2012;119(22):5066-5068.
43. Fishman D, Faulds G, Jeffery R, et al. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest. 1998;102(7):1369-1376.